Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib in Refractory Chronic Spontaneous Urticaria
NCT03137069Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of fenebrutinib in chronic spontaneous urticaria (CSU) (6 cohorts), sponsored by Genentech. Primary endpoint: Urticaria Activity Score Over 7 Days at Day 57. Started May 2017; status: completed.
02
Drugs
fenebrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03137069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137069.